Abstract
Immune checkpoint inhibitors (ICIs) are drugs growingly employed in the treatment of cancers but there are still uncertainties about their possible role in the risk of developing non-tuberculous mycobacteria (NTM) infections.
To understand this, we performed a systematic review of the literature including studies published between 20/06/2012–20/06/2022 which described the occurrence of NTM infections among patients treated with ICIs.
Overall, we included 7 studies describing 9 patients with NTM infection occurring during ICIs therapy.
NTM infections occurring during ICIs therapy are mainly caused by germs belonging to the Mycobacterium avium complex, involve primarily the lungs, on average 1 year after the start of treatment and are not associated with immunosuppressive treatments.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Andrea Lombardi reports the following relationships outside the submitted work; personal fees received from Insmed Italia for lectures, presentations, speakers bureaus, manuscript writing or educational events; personal fees from Gilead Science lc for attending meetings.
Conflict of interest: Andrea Gramegna reports the following relationships outside the submitted work; consulting fees received from Insmed and Vertex; payment or honoraria for lectures, presentations, speakers bureaus, bureaus, manuscript writing or educational events received from Grifols, Chiesi, GSK, Zambon and Insmed.
Conflict of interest: Francecso Blasi reports the following relationships outside the submitted work; grants and personal fees from AstraZeneca, grants and personal fees from Chiesi, personal fees from Grifols, grants and personal fees from GSK, personal fees from Guidotti, personal fees from Insmed, grants and personal fees from Menarini, personal fees from Novartis, personal fee from OM pharma, personal fees from Pfizer personal fees, personal fees from Janssen, personal fees from Vertex, personal fees from Viatris, personal fees from Zambon.
Conflict of interest: The remaining authors have nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received July 21, 2022.
- Accepted September 8, 2022.
- Copyright ©The authors 2022
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org
